Real-world data show DoxyPEP implementation among PrEP users significantly reduces the incidence of chlamydia and syphilis.

A brand new drug might be more effective at preventing HIV than current methods. Many people take daily oral antiretroviral medication—known as PrEP (pre-exposure prophylaxis)—to protect themselves ...

The CDC estimates 2.2 million Americans could benefit from HIV prevention drugs, but just over a quarter of that group have ...

HIV pre-exposure prophylaxis (PrEP) is an effective and safe intervention for individuals with behaviors that are considered high risk for acquiring HIV infection. Despite the success of this ...

Among individuals using HIV pre-exposure prophylaxis (HIV PrEP), doxycycline post-exposure prophylaxis (doxyPEP) was associated with a substantial decline in chlamydia and syphilis incidence.

Cabotegravir demonstrated efficacy as a long-acting PrEP, with no new HIV cases in the PILLAR trial over 12 months. The combination of cabotegravir and rilpivirine showed high viral suppression rates ...

Please provide your email address to receive an email when new articles are posted on . Those living in Black or Hispanic neighborhoods or who were on Medicaid had lower proportions of new PrEP use.

Allowing people to access HIV prevention treatment through community pharmacies could be a "game-changer" in the fight against the virus, experts have said. While most pre-exposure prophylaxis (PrEP) ...

Pre-exposure prophylaxis (PrEP) is a medication regimen that is used to protect at-risk populations from HIV infection. The FDA approved the drug TRUVADA ...